Literature DB >> 10077227

The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line.

M Huang1, G Liu.   

Abstract

The innate drug resistance of human hepatocellular carcinoma (HCC) Bel7402 cell line was studied in vitro. MTT assay showed that Bel7402 cells were innately resistant to doxorubicin (Dox), and even more resistant to vincristine (VCR). This resistance could be effectively reversed by verapamil (Ver), one of the classical multidrug resistance (MDR) modulating agents. However, the differences in 5-fluorouracil (5-FU) toxicity between these two cell lines is much less and the resistance of Bel7402 cells could only be slightly reversed by Ver, which may be experimental noise. Immunocytochemical staining using anti-p-glycoprotein monoclonal antibody JSB-1 indicated that the expression of the P-glycoprotein (P-gp) in the innate Bel7402 cells was elevated compared with the sensitive KB cells. The accumulation of Dox in innate resistant Bel7402 cells was 50.7% lower than that in sensitive KB cells by using spectrofluometric analyses, and the accumulation of Dox increased 1.6 fold in Bel7402 cells in the presence of Ver. The susceptibility of Dox-induced apoptosis was also increased in the presence of Ver by using flow cytometric assay and DNA fragmentation quantitative assay as well as by Hoechst 33258 staining. It appears that the innate Bel7402 cells might be useful in screening new antitumour drugs or new chemosensitisers which could overcome the innate or acquired resistant mechanism, and the toxicity and reversal effects with 5-FU are different from those known to be P-gp substrates such as VCR, Dox, and taxol.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077227     DOI: 10.1016/s0304-3835(98)00280-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells.

Authors:  Yinghui Fu; Jian Huang; Ke-Sheng Wang; Xin Zhang; Ze-Guang Han
Journal:  Mol Biol Rep       Date:  2010-04-06       Impact factor: 2.316

2.  The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis.

Authors:  Jing Jin; Hua Sun; Huailing Wei; Gengtao Liu
Journal:  Invest New Drugs       Date:  2007-04       Impact factor: 3.850

Review 3.  Locoregional and systemic therapy for hepatocellular carcinoma.

Authors:  Olumide B Gbolahan; Michael A Schacht; Eric W Beckley; Thomas P LaRoche; Bert H O'Neil; Maximilian Pyko
Journal:  J Gastrointest Oncol       Date:  2017-04

4.  The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.

Authors:  Halla S Nimeiri; Deepti A Singh; Kristen Kasza; David A Taber; Rafat H Ansari; Everett E Vokes; Hedy L Kindler
Journal:  Invest New Drugs       Date:  2009-08-11       Impact factor: 3.850

5.  Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

Authors:  El Mehdi Tazi; Ismail Essadi; Hind M'rabti; Anass Touyar; Pr Hassan Errihani
Journal:  N Am J Med Sci       Date:  2011-04

Review 6.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

7.  Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

8.  Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.

Authors:  Rammohan Devulapally; Kira Foygel; Thillai V Sekar; Juergen K Willmann; Ramasamy Paulmurugan
Journal:  ACS Appl Mater Interfaces       Date:  2016-12-02       Impact factor: 9.229

9.  A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).

Authors:  Jennifer J Knox; Sharlene Gill; Timothy W Synold; James J Biagi; Pierre Major; Ron Feld; Christine Cripps; Nancy Wainman; Elizabeth Eisenhauer; Lesley Seymour
Journal:  Invest New Drugs       Date:  2008-01-15       Impact factor: 3.850

10.  The critical size of gold nanoparticles for overcoming P-gp mediated multidrug resistance.

Authors:  Yuqian Jiang; Zheng Wang; Wei Duan; Lingyan Liu; Mahan Si; Xiaoyuan Chen; Chen-Jie Fang
Journal:  Nanoscale       Date:  2020-06-17       Impact factor: 7.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.